



THE WHITE HOUSE
WASHINGTON

COVID-19 Press Briefing

October 22, 2021



Daily Change in COVID-19 Cases, US

January 22, 2020 – October 20, 2021

TOTAL Cases Reported Since 1/22/20

45,149,234

NEW Cases Reported to CDC on 10/20/21

73,931

Change in 7-Day Case Average


-15.1%

Current 7-Day Case Average (10/14/21 - 10/20/21)

73,079

Prior 7-Day Case Average (10/7/21 - 10/13/21)

86,046



New Admissions of Patients with Confirmed COVID-19, US

August 1, 2020 – October 19, 2021

Patients Currently Hospitalized with COVID on 10/19/21

47,775

New Admissions on 10/19/21

5,974

Peak in New Admissions (1/5/21)

17,958

Change in 7-Day Average of New Admissions


-10.3%

Current 7-Day Average of New Admissions (10/13/21 - 10/19/21)

6,004

Prior 7-Day Average of New Admissions (10/6/21 - 10/12/21)

6,695



Daily Change in COVID-19 Deaths, US

January 22, 2020 – October 20, 2021

TOTAL Deaths Reported Since 1/22/2020

730,368

NEW Deaths Reported to CDC on 10/20/21

1,537

Change in 7-Day Death Average

-4.3%

Current 7-Day Death Average (10/14/21 - 10/20/21)


1,253

Prior 7-Day Death Average (10/7/21 - 10/13/21)

1,309

Forecasted Total Deaths by 11/13/21

748,000 to 769,000



Recent Developments with COVID-19 Vaccine Boosters

- Mix and match boosting
- Data from Israel
- Pfizer/BioNTech phase 3 clinical trial data




Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report

RL Atmar, JH Beigel et al. for the DMID 21-0012 Study Group

- N= 456 adults who previously had received a full regimen of any of three EUA or approved COVID-19 vaccines
- Additional booster dose of any of these vaccines 12 or more weeks after 2nd dose was safe and immunogenic
- **Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations**
- **Homologous** boost increased neutralizing antibody titers 4.2-20-fold; **heterologous** boost increased titers 6.2-76-fold.

Mix and Match Studies with COVID-19 Vaccines Measuring Neutralizing Antibody Titers




Source: Lyke et al. VRBPAC Oct 14-15, 2021



Absolute Rates of Confirmed Infections per 100,000 Risk-Days in Israel

12+ days following booster versus 2nd dose only

Based on data from booster eligibility in age group until 10/4



Sources: M Bar-On et al. *medRxiv*, 10/7/2021;
S Alroy-Preis & R Milo, FDA VRBAPC meeting, 10/14/2021.



Protection Across Age Groups of BNT162b2 Vaccine Booster against COVID-19

M Bar-On, R Milo et al.

- N= 4.6M people in Israel, July 30 to Oct. 6, 2021
- Severe illness rates 12 more days after booster dose were **18.7-fold lower for ages 60+** and **22.0-fold lower for ages 40-60**, compared to non-booster group

Phase 3 Clinical Trial Data Show High Efficacy of a Booster Dose of Pfizer/BioNTech COVID-19 Vaccine

- **Announcement by companies, Oct. 21, 2021**
- **Randomized, controlled trial; n= >10,000 people who previously received the Pfizer-BioNTech primary two-dose series**
- **30- μ g booster dose had relative vaccine efficacy of 95.6% compared to no booster during period when Delta was predominant**
 - 5 cases of COVID-19 in the booster group; 109 cases in the non-boosted group
- **Favorable safety profile**





THE WHITE HOUSE
WASHINGTON

WH.GOV